# To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine (VITHA-A)

> **NCT03654677** · PHASE3 · COMPLETED · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 253 (actual)

## Conditions studied

- Hepatitis A Vaccine

## Interventions

- **BIOLOGICAL:** inactivated hepatitis A vaccine
- **BIOLOGICAL:** Havrix Inj

## Key facts

- **NCT ID:** NCT03654677
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-19
- **Primary completion:** 2018-10-12
- **Final completion:** 2019-01-31
- **Target enrollment:** 253 (ACTUAL)
- **Last updated:** 2025-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03654677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03654677, "To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine (VITHA-A)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03654677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*